Last updated 2026-07-20
- Raised $19.5M Series A led by LionBird, Sep 2023
- Raised Seed round led by LionBird, Sep 2021
Total raised
$19.5M
Last: Undisclosed Round 2023-10
Stage
Seed
Founded
2021
Headcount
20
HQ
Tel Aviv, Israel
Sector
Health Tech & Life Sciences
About
Mana.bio is a biotechnology company that leverages Artificial Intelligence (AI) and machine learning (ML) to design and optimize lipid nanoparticles (LNPs) for programmable drug delivery. Their platform aims to deliver RNA and gene therapies to specific extrahepatic tissues in the body, addressing a critical bottleneck in genetic medicines. The company's technology integrates machine learning and nanotechnology to identify formulations of lipid nanoparticle drug delivery systems. They offer Mina, an AI agent for lipid nanoparticles, to assist scientists in exploring literature, predicting LNP properties, and optimizing formulations.
Funding history · 2 rounds · $19.5M total
2023-09
A Round
$19.5M
★ LionBird★ NFX Capital★ Base4 Capital★ Andreessen Horowitz★ Technion Research & Development Foundation
2021-09
Seed
Undisclosed
★ LionBird★ NFX Capital
Headcount over time
From 31 (2022-03) to 20 (2026-03) · -11 (-35%) · 14 points · source: Finder history + radar grounding
Q&A
- What is Mana.bio's primary focus?
- Mana.bio specializes in AI-based drug-delivery solutions, with a focus on gene therapy.
- When was Mana.bio founded?
- Mana.bio was founded in October 2021.
- What is Mana.bio's total funding to date?
- Mana.bio has raised a total of $24,500,000 USD.
- When was Mana.bio's most recent funding round and how much was raised?
- Mana.bio's most recent funding round was in October 2023, raising $19,500,000 USD.
- Which investors participated in Mana.bio's October 2023 funding round?
- The October 2023 funding round included investors such as LionBird and Technion Research &.
- Who are the co-founders of Mana.bio?
- The co-founders of Mana.bio are Yogev Debbi (Co-founder & CEO) and Roy Nevo (Co-founder & CTO).
- What technology does Mana.bio utilize for its drug delivery systems?
- Mana.bio integrates machine learning and nanotechnology to identify formulations of lipid nanoparticles for drug delivery systems.
Team · 4
Yogev Debbi
Founder · CEO
Roy Nevo
Founder · CTO
Avi Schroeder
Founder · Scientific Co-founder
Kira Radinsky
Founder · Scientific Co-founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Artificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesLife SciencesBiotechnology
Business model
B2B
Highlights
Verified
Tags
pharmaceuticalsmachine-learningnanotechnologyartificial-intelligencegeneticsdrug-deliverycell-therapytherapeutics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | mana.bio/ |
|---|---|
| linkedin.com/company/76563098 |
Identifiers & details
| Legal name | Mana Bio Ltd. |
|---|---|
| Founded | 2021 |
| Employees (exact) | 20 |
| Offices | Tel Aviv-Yafo |
Radar intelligence
Patents
| EPO | 4 |
|---|
Web history (Wayback)
| Domain | mana.bio |
|---|
Certificate / subdomain footprint
| Subdomains | 10 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516477247 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2021-10-14 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 5 — shares_capital (2), other (1), annual_report (2) |
| Registered address | המלאכה 2 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2026-04-27 | הקצאת מניות |
| 2026-04-20 | שינוי בתקנון |
| 2025-09-08 | דו~ח שנתי-הוספת בעל תפקיד |
| 2025-09-08 | דו~ח שנתי-הסרת בעל תפקיד |
| 2025-12-04 | העברת מניות |